Annotation of Swissmedic Label for norfloxacin and G6PD
PharmGKB ID
Summary
The Swiss drug label for norfloxacin (Norsol) states that patients with G6PD deficiency may experience hemolytic anemia.
Please note that this drug label annotation was created from a collaboration between PharmGKB and Pharmaceutical Care Research Group in University of Basel in 2019. The label has not been subsequently reviewed or updated.
Annotation
Please note that the information contained within this drug label annotation is available through a collaboration with the Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under "Source" below.
Excerpt from the drug label for norfloxacin (Norsol):
Precautions: Patients with latent or existing defect of glucose-6-phosphate dehydrogenase activity treated with quinolone antibiotics including Norsol were rarely reported to have hemolytic reactions (see "Adverse effects").
Adverse effects: Rarely: Hemolytic anemia sometimes associated with glucose-6-phosphate dehydrogenase deficiency.
For the complete drug label text with pharmacogenetic information highlighted, see the norfloxacin drug label (in German).
*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.
Evidence for Clinical Annotations
This annotation has been used as evidence for the following clinical annotations.
History
No history available.